0.0155
0.0000
(0.00%)
At close: April 10 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
20,428
29,597
18,390
20,610
23,167
Cost of Revenue
1,083
1,342
2,588
3,312
2,248
Gross Profit
19,345
28,255
15,802
17,298
20,919
Operating Expense
19,327
24,715
22,388
23,426
20,951
Operating Income
18
3,540
-6,586
-6,128
-32
Net Non Operating Interest Income Expense
-5,799
-6,702
-4,333
-2,340
-5,188
Other Income Expense
2,196
-630
354
-7,453
6,193
Pretax Income
-3,585
-3,792
-10,565
-15,921
973
Tax Provision
-89
-59
60
25
-381
Net Income Common Stockholders
-3,496
-3,733
-10,625
-15,946
1,354
Diluted NI Available to Com Stockholders
-3,496
-3,733
-10,625
-15,946
1,354
Basic EPS
-0.05
-0.07
-0.21
-0.32
0.03
Diluted EPS
-0.05
-0.07
-0.21
-0.32
0.03
Basic Average Shares
61,063.1830
53,105.3880
49,439.8670
49,253.1560
48,897.0040
Diluted Average Shares
61,063.1830
53,105.3880
49,439.8670
49,253.1560
48,897.0040
Total Operating Income as Reported
18
3,540
-6,586
-6,128
-32
Total Expenses
20,410
26,057
24,976
26,738
23,199
Net Income from Continuing & Discontinued Operation
-3,496
-3,733
-10,625
-15,946
1,354
Normalized Income
-5,994.3967
-4,799.1495
-12,415.9300
-12,500.4000
-4,670.6900
Interest Income
594
681
680
761
801
Interest Expense
6,393
7,383
5,013
3,101
5,989
Net Interest Income
-5,799
-6,702
-4,333
-2,340
-5,188
EBIT
2,808
3,591
-5,552
-12,820
6,962
EBITDA
2,831
3,623
-5,499
-12,761
7,022
Reconciled Cost of Revenue
1,083
1,342
2,588
3,312
2,248
Reconciled Depreciation
23
32
53
59
60
Net Income from Continuing Operation Net Minority Interest
-3,496
-3,733
-10,625
-15,946
1,354
Total Unusual Items Excluding Goodwill
2,562
1,083
2,267
-4,720
8,253
Total Unusual Items
2,562
1,083
2,267
-4,720
8,253
Normalized EBITDA
269
2,540
-7,766
-8,041
-1,231
Tax Rate for Calcs
0
0
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
63.6033
16.8505
476.0700
-1,274.4000
2,228.3100
12/31/2020 - 8/22/1996
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ATNF 180 Life Sciences Corp.
0.8495
+22.94%
ENVB Enveric Biosciences, Inc.
1.2500
+6.84%
ZNTL Zentalis Pharmaceuticals, Inc.
1.2300
+8.85%
TCBPY TC Biopharm (Holdings) Plc
0.2500
-16.67%
DRMA Dermata Therapeutics, Inc.
0.8080
+3.70%
ALXO ALX Oncology Holdings Inc.
0.4900
+2.08%
OTLK Outlook Therapeutics, Inc.
1.3800
+11.29%
GOVX GeoVax Labs, Inc.
1.0200
+7.31%
ONCO Onconetix, Inc.
0.0623
+7.41%
CDT Conduit Pharmaceuticals Inc.
0.9101
-14.94%